Seasonal Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Seasonal Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The seasonal allergic rhinitis market reached a value of US$ 10.5 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2023. Looking forward, IMARC Group expects the top 7 markets to reach US$ 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034.

The seasonal allergic rhinitis market has been comprehensively analyzed in IMARC's new report titled "Seasonal Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Seasonal allergic rhinitis, commonly called hay fever, refers to an allergic reaction that occurs in response to certain allergens present in the environment during specific seasons. It is characterized by inflammation of the nasal passages, resulting in various symptoms, such as sneezing, itching, a runny or stuffy nose, watery eyes, etc. Some individuals suffering from this ailment may also experience fatigue, coughing, sore throat, headache, nasal congestion, itchiness in the throat or ears, postnasal drip, impaired sleep cycle, etc. These symptoms can significantly impact daily activities and the overall quality of life. The diagnosis of seasonal allergic rhinitis is usually based on the patient's medical history, clinical signs, and physical examination. A healthcare provider may recommend skin prick tests to identify specific allergens that trigger the allergic reaction. Furthermore, radioallergosorbent testing is utilized to measure the amount of certain IgE antibodies in the blood that may be indicative of the disease. In some cases, a nasal provocation test is also required, which involves the introduction of a small amount of allergen directly into the nose to detect the cause of underlying symptoms.

The increasing cases of overactivation of the immune system which results in the release of histamine and other chemicals, thereby leading to an allergic response, are primarily driving the seasonal allergic rhinitis market. Additionally, the rising incidences of exposure to pollen from grasses, trees, weeds, etc., which cause inflammation and irritation in the airways, are also creating a positive outlook for the market. Moreover, the widespread adoption of intranasal corticosteroids, including fluticasone, budesonide, mometasone, etc., to minimize the symptoms of the ailment is further bolstering the market growth. Apart from this, the escalating application of effective medications, like antihistamines, since they work by blocking the histamine receptors and reducing the swelling of blood vessels in the nasal passages to alleviate discomfort among patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of allergy shots to treat this condition, owing to their several benefits, such as long-term relief, improved quality of life, and decreased need for other interventions, is expected to drive the seasonal allergic rhinitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the seasonal allergic rhinitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for seasonal allergic rhinitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the seasonal allergic rhinitis market in any manner.

Recent Developments:
In February 2024, Novartis disclosed that the US Food and Drug Administration (FDA) approved Xolair (omalizumab) to manage symptoms in people with moderate to severe seasonal allergic rhinitis. This therapy helps to lower blood eosinophil counts, which is associated with lower serum-free IgE levels in patients.
In August 2023, Inimmune Corporation initiated dosing of the first participant in its phase 1/1b First-in-Human clinical trial for INI-2004, a TLR4 agonist developed as a prospective treatment for seasonal allergic rhinitis.
In May 2023, Bausch Health Companies Inc. announced the launch of its new prescription treatment, RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) across Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis in adults, adolescents, and children aged 6 years and older. RYALTRIS is an intra-nasal spray that should not be taken orally, sprayed into the eyes or ears, or administered to the skin.
In May 2023, Altamira Therapeutics Ltd. revealed positive and statistically significant findings from a randomized controlled NASAR clinical trial of its Bentrio nasal spray in individuals suffering from seasonal allergic rhinitis. Bentrio nasal spray is a drug- and preservative-free gel emulsion that aids in protecting against dust mites and other airborne allergens like pollen.

Key Highlights:
About one-quarter (24.7%) of adults aged 18–44, 27.9% of adults aged 45–64, 26.4% of adults aged 65–74, and 21.7% of adults aged 75 and over had a seasonal allergy in 2021, as per the data of National Center for Health Statistics.
According to estimates regularly put forward, the prevalence of allergic respiratory diseases such as seasonal rhinitis has nearly doubled in industrialized countries in the past 20 years.
Non-Hispanic White adults (28.4%) were more likely to have a seasonal allergy compared with non-Hispanic Black (24.0%), Hispanic (18.8%), and non-Hispanic Asian (17.0%) adults.
The prevalence of seasonal allergic rhinitis in children groups were 16.1% in the city center compared to 6.7% in the rural area.
Over 26 percent of adults in the United States are affected by seasonal allergies, making it the most common allergic condition, as reported by the Centers for Disease Control and Prevention.
The Centers for Disease Control and Prevention researchers also found that seasonal allergies are more common among women (29.9%) than men (21.1%).

Drugs:
Astelin (azelastine hydrochloride) nasal spray is an antihistamine that inhibits sneezing, itching, runny nose, and numerous other nasal symptoms of seasonal allergies. The recommended dose of Astelin nasal spray in adults and children 12 years and older with seasonal allergic rhinitis is one or two sprays per nostril twice daily, whereas the dose in children 5 years to 11 years of age is one spray per nostril twice daily. Each spray of Astelin nasal spray delivers a volume of 0.137 mL solution containing 137 mcg of azelastine hydrochloride, which exhibits histamine H1-receptor antagonist activity in patients.

IRL-201104 is an under development immunomodulatory drug by Revolo Biotherapeutics for the treatment of seasonal allergic rhinitis. This therapeutic compound is a peptide derived from mycobacterium tuberculosis chaperonin 60.1 that reduces neutrophil invasion into the lung, thereby decreasing inflammation. It is administered through intravenous and subcutaneous routes to reset the immune response with the potential for inducing long-term disease remission.

REGN5713-5714-5715 is an investigational molecule to treat seasonal allergic rhinitis. The therapeutic substance consists of three human monoclonal antibodies, including REGN5713, REGN5714, REGN5715. It is delivered via intravenous and subcutaneous routes. The medicinal agent works by addressing pollen allergen Bet v 1 in patients.


Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the seasonal allergic rhinitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the seasonal allergic rhinitis market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:
This report also provides a detailed analysis of the current seasonal allergic rhinitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:
Market Insights

How has the seasonal allergic rhinitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the seasonal allergic rhinitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the seasonal allergic rhinitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of seasonal allergic rhinitis across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of seasonal allergic rhinitis by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of seasonal allergic rhinitis by gender across the seven major markets?
How many patients are diagnosed (​2018-2034​) with seasonal allergic rhinitis across the seven major markets?
What is the size of the seasonal allergic rhinitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of seasonal allergic rhinitis?
What will be the growth rate of patients across the seven major markets?

Seasonal Allergic Rhinitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for seasonal allergic rhinitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the seasonal allergic rhinitis market?
What are the key regulatory events related to the seasonal allergic rhinitis market?
What is the structure of clinical trial landscape by status related to the seasonal allergic rhinitis market?
What is the structure of clinical trial landscape by phase related to the seasonal allergic rhinitis market?
What is the structure of clinical trial landscape by route of administration related to the seasonal allergic rhinitis market?